×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
DRMA – dermata therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
DRMA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/17
09:21 am
drma
AVAVA™ Announces Industry Heavyweights Clint Carnell as Executive Chairman and Mary Fisher to Its Board of Directors [Yahoo! Finance]
Medium
Report
AVAVA™ Announces Industry Heavyweights Clint Carnell as Executive Chairman and Mary Fisher to Its Board of Directors [Yahoo! Finance]
12/16
09:27 am
drma
Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM) [Yahoo! Finance]
Low
Report
Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM) [Yahoo! Finance]
12/16
09:00 am
drma
Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)
High
Report
Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)
12/10
09:22 am
drma
Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne [Yahoo! Finance]
Medium
Report
Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne [Yahoo! Finance]
12/10
09:00 am
drma
Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne
Medium
Report
Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne
12/3
09:18 am
drma
Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne [Yahoo! Finance]
Medium
Report
Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne [Yahoo! Finance]
12/3
09:00 am
drma
Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
Medium
Report
Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
11/13
04:15 pm
drma
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Medium
Report
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
05:07 pm
drma
Form SC 13G/A Dermata Therapeutics, Filed by: ARMISTICE CAPITAL, LLC
Medium
Report
Form SC 13G/A Dermata Therapeutics, Filed by: ARMISTICE CAPITAL, LLC
11/14
06:01 am
drma
Form 8-K Dermata Therapeutics, For: Nov 13
Medium
Report
Form 8-K Dermata Therapeutics, For: Nov 13
11/13
04:17 pm
drma
Form 10-Q Dermata Therapeutics, For: Sep 30
Medium
Report
Form 10-Q Dermata Therapeutics, For: Sep 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: